Literature DB >> 19181773

Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.

H S Malhotra1, K K Jain, A Agarwal, M K Singh, S K Yadav, M Husain, N Krishnani, R K Gupta.   

Abstract

BACKGROUND AND OBJECTIVES: Diagnosis of tumefactive demyelinating lesions (TDLs) is challenging to both clinicians and radiologists. Our objective in this study was to analyze and characterize these lesions clinically, biochemically, electrophysiologically, and on imaging.
METHODS: A retrospective analysis with prospective follow-up of 18 cases of TDLs was performed. Imaging included T2-, T1-weighted, fluid-attenuated inversion recovery (FLAIR), post-contrast T1-weighted, diffusion weighted imaging (DWI), and proton magnetic resonance spectroscopy (PMRS).
RESULTS: All the lesions appeared hyperintense on T2 and FLAIR images. Increased Apparent diffusion coefficient (ADC) (0.93-2.21 x 10(-3) mm(2)/s) in centre of the lesion was seen in 14/18 cases; however, peripheral restriction (ADC values 0.55-0.64 x 10(-3) mm(2)/s) was noted in 11/18 cases. In all, 13/18 cases showed contrast enhancement with open ring (n = 5), complete ring (n = 1), minimal (n = 4), and infiltrative (n = 3) pattern of enhancement. Nine of these 13 cases also showed venular enhancement. On PMRS, nine showed glutamate/glutamine (Glx) at 2.4 ppm.
CONCLUSION: Clinical features along with several MRI characteristics such as open ring enhancement, peripheral restriction on DWI, venular enhancement, and presence of Glx on spectroscopy may be rewarding in differentiating TDLs from neoplastic lesions.

Entities:  

Mesh:

Year:  2009        PMID: 19181773     DOI: 10.1177/1352458508097922

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  22 in total

1.  Differentiation of tumefactive demyelinating lesions from high-grade gliomas with the use of diffusion tensor imaging.

Authors:  C H Toh; K-C Wei; S-H Ng; Y-L Wan; M Castillo; C-P Lin
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-15       Impact factor: 3.825

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.

Authors:  Rocco Totaro; C Di Carmine; A Splendiani; S Torlone; L Patriarca; C Carrocci; S Sciamanna; C Marini; A Carolei
Journal:  Neurol Sci       Date:  2016-04-15       Impact factor: 3.307

4.  Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.

Authors:  Mirja Wallner-Blazek; Alex Rovira; Massimo Fillipp; Mara A Rocca; David H Miller; Klaus Schmierer; Jette Frederiksen; Achim Gass; Hugo Gama; Charles P Tilbery; Antonio J Rocha; José Flores; Frederik Barkhof; Alexandra Seewann; Jacqueline Palace; Tarek Yousry; Xavier Montalban; Christian Enzinger; Franz Fazekas
Journal:  J Neurol       Date:  2013-04-26       Impact factor: 4.849

5.  Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.

Authors:  G Balloy; J Pelletier; L Suchet; C Lebrun; M Cohen; P Vermersch; H Zephir; E Duhin; O Gout; R Deschamps; E Le Page; G Edan; P Labauge; C Carra-Dallieres; L Rumbach; E Berger; P Lejeune; P Devos; J-B N'Kendjuo; M Coustans; E Auffray-Calvier; B Daumas-Duport; L Michel; F Lefrere; D A Laplaud; C Brosset; P Derkinderen; J de Seze; S Wiertlewski
Journal:  J Neurol       Date:  2018-07-27       Impact factor: 4.849

Review 6.  The pathological spectrum of CNS inflammatory demyelinating diseases.

Authors:  Wei Hu; Claudia F Lucchinetti
Journal:  Semin Immunopathol       Date:  2009-09-25       Impact factor: 9.623

7.  Development of a standardized MRI scoring tool for CNS demyelination in children.

Authors:  L H Verhey; H M Branson; S Laughlin; M M Shroff; S M Benseler; B M Feldman; D L Streiner; J G Sled; B Banwell
Journal:  AJNR Am J Neuroradiol       Date:  2013-01-24       Impact factor: 3.825

8.  Demyelinating lesions behaving like aggressive tumours on advanced MRI techniques.

Authors:  Brainner Campos Barbosa; Edson Marchiori; Caio Leal Leidersnaider; Lara Brandao; Mauricio Castillo
Journal:  Neuroradiol J       Date:  2019-01-22

Review 9.  Perfusion MRI: the five most frequently asked clinical questions.

Authors:  Marco Essig; Thanh Binh Nguyen; Mark S Shiroishi; Marc Saake; James M Provenzale; David S Enterline; Nicoletta Anzalone; Arnd Dörfler; Àlex Rovira; Max Wintermark; Meng Law
Journal:  AJR Am J Roentgenol       Date:  2013-09       Impact factor: 3.959

10.  Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.

Authors:  Marc C Mabray; Benjamin A Cohen; Javier E Villanueva-Meyer; Francisco E Valles; Ramon F Barajas; James L Rubenstein; Soonmee Cha
Journal:  AJR Am J Roentgenol       Date:  2015-11       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.